Picato 500 micrograms/gram gel

  • Name:

    Picato 500 micrograms/gram gel

  • Company:
    info
  • Active Ingredients:

    Ingenol mebutate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/11/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 12/11/2019
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

LEO Pharma

LEO Pharma

Company Products

Medicine NameActive Ingredients
Medicine Name Dovobet Gel Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Dovobet Ointment Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Dovonex Cream Active Ingredients Calcipotriol hydrate
Medicine Name Dovonex Ointment Active Ingredients Calcipotriol
Medicine Name Dovonex Psoriasis 50 microgram/g ointment Active Ingredients Calcipotriol
Medicine Name Enstilar Cutaneous Foam Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Fucibet Cream Active Ingredients Betamethasone Valerate, Fusidic Acid
Medicine Name Fucibet Lipid Cream Active Ingredients Betamethasone Valerate, Fusidic Acid
Medicine Name Fucidin Cream Active Ingredients Fusidic Acid
Medicine Name Fucidin H Cream Active Ingredients Fusidic Acid Hemihydrate, Hydrocortisone Acetate
Medicine Name Fucidin Ointment Active Ingredients Sodium Fusidate
Medicine Name Fucidin Suspension Active Ingredients Fusidic Acid Hemihydrate
Medicine Name Fucidin Tablets Active Ingredients Sodium Fusidate
Medicine Name innohep 10,000 IU in 0.5 ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 10,000 IU/ml Solution for Injection (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 12,000 IU in 0.6ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 14,000 IU in 0.7 ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 16,000 IU in 0.8ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 18,000 IU in 0.9ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 2,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name Innohep 20,000 IU/ml Solution for Injection (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 3,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 4,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 8,000 IU in 0.4ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name Kyntheum 210 mg Solution for Injection Active Ingredients Brodalumab
1 - 0 of 40 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 November 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Addition of Black Inverted Triangle

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of black triangle and update to section 4.4:

 

Keratoacanthoma, basal cell carcinoma, Bowen’s disease, squamous cell carcinoma

Reports of keratoacanthoma, basal cell carcinoma, Bowen’s disease, squamous cell carcinoma occurring within the treatment area with a time to onset ranging from weeks to months following use of ingenol mebutate gel have been received from a post-authorisation clinical trial (see section 5.1) and post-marketing. Ingenol mebutate should be used with caution in patients with a history of cutaneous malignancy.

Health care professionals should advise patients to be vigilant for any lesions developing within the treatment area and to seek medical advice immediately should any occur.”

Updated on 12 November 2019 PIL

Reasons for updating

  • Addition of Black Inverted Triangle

Updated on 25 July 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 25 July 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Removal of black triangle

Updated on 20 July 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors
  • Removal of black triangle

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·       Black triangle warning removed

·       Section 4.2 – The information regarding time to assessment of optimal treatment effect and repeat treatment has been relocated within the section

·       Section 4.2 – The information regarding immunocompromised patientshas been relocated within the section

·       Section 4.2 – Duplicate information regarding applying to a 25cm2 area has been removed

·       Section 4.2 – The posology information for treatment of the neck has been clarified

·       Section 4.4 – A warning regarding reports of keratoancanthoma has been added

·       Section 4.8 – The introduction to tabulated list of adverse reactions has been amended to clarify this also refers to post-marketing reports

·       Section 5.1 – Clinical trial data relating to ingenol mebutate gel 600 mcg/g applied to a larger treatment area have been added

·       Section 5.2 – A subheading “absorption” has been added

·       Section 9 – The date of last renewal has been updated

·       Section 10 – The date of revision of the text has been updated

·       Minor editorial changes have been made

Updated on 20 July 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 7 February 2017 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- In Section 4.8, application site scarring has been added as a rare event
- In Section 7, the marketing authorisation holder has been changed from LEO Pharma A/S, Denmark to LEO Laboratories Ltd, Ireland
- The date of revision has been updated

Updated on 7 February 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 3 June 2016 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 4 May 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 4 May 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- In section 4.4 (special warnings and precautions for use) new warnings regarding eye exposure are added
- In section 4.8 (undesirable effects) new side effects of hypersensitivity (including angioedema), chemical conjunctivitis, corneal burn and application site pigmentation changes are added
- The date of revision is updated

Updated on 10 September 2015 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 21 August 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

$0InSection 4.2 information on using appropriate strengths for treatment areas isadded.  Information on repeat treatment is added.$0$0In Section 4.8 long term data from the use after cryotherapy and repeat usestudies are added.$0$0In Section 5.1 results from the use after cryotherapy and repeat use studiesare added.$0

Updated on 19 August 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to dosage and administration

Updated on 12 March 2014 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Addition of black triangle

Updated on 19 December 2013 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Addition of black triangle
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.5 Interaction with other medicinal products and other forms of interaction

The following sentence has been modified; Interactions with systemically absorbed medicinal

products are considered unlikely

 

as Picato is not absorbed systemically.

 

The word 'unlikely' was previously minimal.

4.6 Fertility, pregnancy and lactation

The wording on breastfeeding has had editorial changes with regard to the infant avoiding physical contact with the treated area - the clinical meaning has not changed;

Breast-feeding

No effects on the breastfed newborn/infant are anticipated as Picato is not absorbed systemically. The

nursing mother should be instructed that physical contact between her newborn/infant and the

treated area should be avoided for a period of 6 hours after application of Picato.

Section 4.8 Undesirable effects

Periorbital oedema has been moved from the MedDRA system organ class 'Skin and subcutaneous tissue disorders' to 'Eye disorders' - the frequency of this adverse reaction has not changed.

The category 'Eye disorders' now has a footnote to state that this category now includes 'Application site swelling on the face or scalp may gravitate to the eye area'.

The adverse event 'Application site pain' now has a footnote to say that it includes 'Application site burning'.

A statement regarding the reporting of adverse events to national authorities has been added to the SmPC - for the UK, this refers to the MHRA Yellowcard system, for Ireland, it refers to the IMB Pharmacovigilance section.

Section 5.1 Pharmacodynamic properties

A sentence regarding the mechanism of action has revised with editorial changes; the revised wording states 'The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised'. The previous wording stated 'The mechansim of action in actinic keratosisis not fully understood.'

Further information has been provided regarding the inflammatory response in the mechanism of action 'local production of proinflammatory cytokines and chemokines' has been added to the following sentence;

In vivo and in vitro models have shown a dual mechanism of action for the effects of ingenol mebutate: 1) induction of local lesion cell death and 2) promoting an inflammatory response characterised by local production of proinflammatory cytokines and chemokines and infiltration of immunocompetent cells.

The heading in Table 2 now provides more information, it is clarifying that the figures displayed refer to median %, the reduction is in lesions, and the results are in actinic keratosis.

The new heading states: 'Table 2 Rates of subjects with complete and partial clearance and median percent (%) lesion reduction in actinic keratosis'.

Section 10 Date of Revision

This has been updated from November 2012 to November 2013.

Updated on 22 January 2013 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 January 2013 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided